Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

This review (2022) explores the evidence to assess the psychological and psychiatric risks associated with psychedelics. It was found that medical risks are often minimal and that nearly all of the negative perceptions of psychological risks associated with psychedelics are not supported by the current evidence.

Authors

  • Neil, J. C.
  • Nutt, D. J.

Published

Journal of Psychopharmacology
meta Study

Abstract

Background: Despite an increasing body of research highlighting their efficacy to treat a broad range of medical conditions, psychedelic drugs remain a controversial issue among the public and politicians, tainted by previous stigmatisation and perceptions of risk and danger.Objective: This narrative review examines the evidence for potential harms of the classic psychedelics by separating anecdotes and misinformation from systematic research.Methods: Taking a high-level perspective, we address both psychological and psychiatric risks, such as abuse liability and potential for dependence, as well as medical harms, including toxicity and overdose. We explore the evidence base for these adverse effects to elucidate which of these harms are based largely on anecdotes versus those that stand up to current scientific scrutiny.Results: Our review shows that medical risks are often minimal and that many - albeit not all - of the persistent negative perceptions of psychological risks are unsupported by the currently available scientific evidence, with the majority of reported adverse effects not being observed in a regulated and/or medical context.Conclusions: This highlights the importance for clinicians and therapists to keep to the highest safety and ethical standards. It is imperative not to be overzealous and to ensure balanced media reporting to avoid future controversies so that much-needed research can continue.

Unlocked with Blossom Pro

Research Summary of 'Adverse effects of psychedelics: From anecdotes and misinformation to systematic science'

Study Details

Cited By (42)

Papers in Blossom that reference this study

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis

Avancena, A. L. V., Kahn, J. G., Marseille, E. et al. · Translational Psychiatry (2025)

Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use

Carhart-Harris, R. L., de Wied, D., Kettner, H. et al. · PNAS (2025)

Side Effects of Microdosing Lysergic Acid Diethylamide and Psilocybin: A Systematic Review of Potential Physiological and Psychiatric Outcomes

Lukasiewicz, K., Modzelewski, S., Stankiewisz, A. et al. · Neuropharmacology (2025)

A review of psychedelics trials completed in depression, informed by European regulatory perspectives

Balabanov, P., Butlen-Ducuing, F., Guizzaro, L. et al. · Neuroscience Applied (2025)

1 cited
The Australia story: Current status and future challenges for the clinical applications of psychedelics

Fitzgerald, P. B., Hunt, P., Nutt, D. J. et al. · British Journal of Clinical Pharmacology (2024)

Safety pharmacology of acute mescaline administration in healthy participants

Humbert-Droz, M. · British Journal of Clinical Pharmacology (2024)

Single-dose 1cp-LSD administration for canine anxiety: a pilot study

Borkel, L. F., Fernández-Borkel, T., García-Serrano, I. et al. · Veterinary Research Communications (2024)

Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors

Carhart-Harris, R. L., Curtin, J., Dunne, J. D. et al. · MedRvix (2024)

4 cited
Psychedelic-assisted psychotherapy: Where is the psychotherapy research?

Aday, J. S., Bradley, E. R., Fernandes-Osterhold, G. et al. · Psychopharmacology (2024)

How Do Psychedelics Reduce Fear of Death?

Letheby, C. · Neuroethics (2024)

11 cited
Show all 42 papers
Personality traits explain the relationship between psychedelic use and less depression in a comparative study

Claesdotter-Knutsson, E., Kajonius, P. J., Sjöström, D. K. · Scientific Reports (2024)

Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression

Aicher, H. D., Bauer, P. R., Ehrenkranz, R. et al. · Psychoactives (2024)

Naturalistic use of psychedelics does not modulate processing of self-related stimuli (but it might modulate attentional mechanisms): An event-related potentials study

Bola, M., Hobot, J., Orłowski, P. et al. · Psychophysiology (2024)

2 cited
Psilocybin enhances insightfulness in meditation: a perspective on the global topology of brain imaging during meditation

Berit, S., Dornbierer, D. A., Hirsch-Hoffmann, M. et al. · Scientific Reports (2024)

Psychiatric risks for worsened mental health after psychedelic use

Carhart-Harris, R. L., Erritzoe, D., Kettner, H. et al. · Journal of Psychopharmacology (2024)

41 cited
Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study

Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Humanistic Psychology (2024)

Strong Bipartisan Support for Controlled Psilocybin Use as Treatment or Enhancement in a Representative Sample of US Americans: Need for Caution in Public Policy Persists

Earp, B. D., Gill, M., Hannikainen, I. R. et al. · AJOB Neuroscience (2024)

10 cited
Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study

Aday, J. S., Bloesch, E. K., Davis, A. K. et al. · Journal of Psychoactive Drugs (2024)

15 cited
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential

Allen, J., Dames, S., Foldi, C. J. et al. · Molecular Psychiatry (2024)

Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study

Borkel, L. F., Del Pino, A. S., Henríquez-Hernández, L. A. et al. · Expert Review of Clinical Pharmacology (2023)

Extended difficulties following the use of psychedelic drugs: A mixed methods study

Evans, J., Ketzitzidou-Argyri, E., McAlpine, R. et al. · PLOS ONE (2023)

123 cited
Psychedelic use and psychiatric risks

Chambers, R., Goldberg, S. B., Hendricks, P. S. et al. · Psychopharmacology (2023)

Back from the rabbit hole. Theoretical considerations and practical guidelines on psychedelic integration for mental health specialists

Greń, J., Kiraly, C., Lasocik, M. et al. · Frontiers in Psychology (2023)

Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis

Carter, B., Cleare, A. J., Ko, K. et al. · Neuropsychiatric Disease And Treatment (2023)

Case analysis of long-term negative psychological responses to psychedelics

Bremler, R., Carhart-Harris, R. L., Erritzoe, D. et al. · Scientific Reports (2023)

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

Barnett, B. S., Claytor, B., Kovacevich, A. et al. · Journal of Psychoactive Drugs (2023)

5 cited
Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing

Aaronson, S. T., Alti, M., Carhart-Harris, R. L. et al. · Psychopharmacology (2023)

Effects of ayahuasca on gratitude and relationships with nature: An open-label, naturalistic study

Adams, A. M., Bloesch, E. K., Davis, A. K. et al. · Psyarxiv (2023)

Meditation Trips: A Thematic Analysis of the Combined Naturalistic Use of Psychedelics With Meditation Practices

Azmoodeh, K., Kamboj, S. K., Thomas, E. · Experimental and Clinical Psychopharmacology (2023)

9 cited
Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline

Pleet, M. M., White, J., Yehuda, R. et al. · Psychedelic Medicine (2023)

Classic Psychedelic Use and Current Meditation Practice

Chambers, R., Goldberg, S. B., Hendricks, P. S. et al. · Mindfulness (2023)

14 cited
Personal Psychedelic Use Is Common Among a Sample of Psychedelic Therapists: Implications for Research and Practice

Aday, J. S., Bradley, E. R., Eaton, N. et al. · Psychedelic Medicine (2023)

Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines

Borkel, L. F., Henríquez-Hernández, L. A., Quintana-Hernández, D. J. et al. · Toxics (2023)

Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands

Evans, J., Lutkajtis, A. · Journal of Psychedelic Studies (2023)

Altered States of Consciousness During Ceremonial San Pedro Use

Bohn, A., Kiggen, M. H. H., Ramaekers, J. G. et al. · International Journal for the Psychology of Religion (2022)

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Desai, S., Du, W., Jain, V. et al. · Children (2022)

5 cited
Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy-A systematized review

Baker, P., Bright, S. J., Bruno, R. et al. · Journal of Psychopharmacology (2022)

Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies

Bühler, K. M., Calleja-Conde, J., Echeverry-Alzate, V. et al. · Addiction Biology (2022)

Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review

Breeksema, J. J., Kamphuis, J., Schoevers, R. A. et al. · Journal of Psychopharmacology (2022)

Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data

Barnett, B. S., Carlo, A. D., Doblin, R. et al. · Journal of Psychopharmacology (2022)

11 cited
Psychedelic replications in virtual reality and their potential as a therapeutic instrument: an open-label feasibility study

Aaru, J., Kaup, K. K., Pikame, J. et al. · Frontiers in Psychiatry (2022)

Motives for the use of serotonergic psychedelics: A systematic review

Basedow, L. A., Kuitunen-Paul, S. · Drug and Alcohol Review (2022)

Your Library